Articles with public access mandates - Emilio Y. Lucero Garcia RojasLearn more
Available somewhere: 7
Therapeutic potential of targeting ß-arrestin
RA Bond, EY Lucero Garcia-Rojas, A Hegde, JKL Walker
Frontiers in pharmacology 10, 124, 2019
Mandates: US National Institutes of Health
Hypoxia inducible factors as central players in the pathogenesis and pathophysiology of cardiovascular diseases
EY Lucero García Rojas, C Villanueva, RA Bond
Frontiers in cardiovascular medicine 8, 709509, 2021
Mandates: US National Institutes of Health
Pathophysiology and pharmacology of G protein-coupled receptors in the heart
A Grogan, EY Lucero, H Jiang, HA Rockman
Cardiovascular research 119 (5), 1117-1129, 2023
Mandates: US National Institutes of Health
A NanoBiT assay to monitor membrane proteins trafficking for drug discovery and drug development
A Reyes-Alcaraz, EY Lucero Garcia-Rojas, EA Merlinsky, JY Seong, ...
Communications Biology 5 (1), 212, 2022
Mandates: US National Institutes of Health, American Heart Association
STEMIN and YAP5SA synthetic modified mRNAs regenerate and repair infarcted mouse hearts
S Xiao, R Liang, E Lucero, BK McConnell, Z Chen, J Chang, S Navran, ...
The journal of cardiovascular aging 2 (3), 2022
Mandates: US National Institutes of Health, American Heart Association, Leducq …
Allosteric modulators for GPCRs as a therapeutic alternative with high potential in drug discovery
A Reyes-Alcaraz, EYL Garcia-Rojas, RA Bond, BK McConnell
Molecular Pharmacology, 2020
Mandates: US National Institutes of Health, American Heart Association
Fusion of the β2‐adrenergic receptor with either Gαs or βarrestin‐2 produces constitutive signaling by each pathway and induces gain‐of‐function in BEAS‐2B cells
EY Lucero‐Garcia Rojas, A Reyes‐Alcaraz, K Ruan, BK McConnell, ...
FASEB BioAdvances 4 (12), 758-774, 2022
Mandates: US National Institutes of Health, American Heart Association
Publication and funding information is determined automatically by a computer program